Bristol-Myers Squibb Company

NYSE: BMY
$58.41
-$0.61 (-1.0%)
Closing Price on November 13, 2024

BMY Articles

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to their...
Deal makers were busy over the weekend. Strategic considerations were more the driver of activity than an improved economy, however. Lions Gate Entertainment (NYSE: LGF) will buy Summit Entertainment...
http://platform.twitter.com/widgets/hub.1324331373.htmlThe U.S. may start legal proceedings against Swiss financial firm Wegelin & Co. based on beliefs that it helped shield Americans from taxes....
The EU continues to work on its bailout fund and may ask the IMF for help. (Reuters) American Airlines parent AMR (NYSE: AMR) files for Chapter 11. (Reuters) S&P cuts its ratings on large...
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
The DJIA jumped above 12,000 in the opening minutes of trading this morning and had topped 12,200 by mid-afternoon. European Union leaders have agreed on a deal that would make up to $1.4 trillion as...
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit...
Drug and medical stocks are not generally thought of as stocks hitting 52-week highs by the investing public.  So what about when a company decides to unlock shareholder value by breaking itself...
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
With fears of a new economic downturn, investors have become concerned about sales and profits of large companies. But there are companies that have already proven themselves in the recent recession....